Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Sees Large Drop in Short Interest

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) was the target of a large drop in short interest in May. As of May 15th, there was short interest totaling 19,598 shares, a drop of 57.4% from the April 30th total of 46,010 shares. Approximately 0.4% of the shares of the stock are short sold. Based on an average trading volume of 28,089 shares, the days-to-cover ratio is presently 0.7 days.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on NEUP shares. HC Wainwright lowered Neuphoria Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, May 15th. Zacks Research upgraded Neuphoria Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 3rd. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Neuphoria Therapeutics currently has an average rating of “Hold” and a consensus price target of $21.00.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Persistent Asset Partners Ltd bought a new stake in shares of Neuphoria Therapeutics during the 3rd quarter valued at $58,000. Commonwealth Equity Services LLC bought a new stake in shares of Neuphoria Therapeutics during the 4th quarter valued at $43,000. XTX Topco Ltd bought a new stake in shares of Neuphoria Therapeutics during the 4th quarter valued at $47,000. Boothbay Fund Management LLC bought a new stake in shares of Neuphoria Therapeutics during the 4th quarter valued at $54,000. Finally, Bridgeway Capital Management LLC bought a new stake in shares of Neuphoria Therapeutics during the 4th quarter valued at $57,000. Institutional investors own 15.90% of the company’s stock.

Neuphoria Therapeutics Trading Down 6.7%

NEUP stock traded down $0.36 during trading on Tuesday, reaching $4.95. 38,233 shares of the stock were exchanged, compared to its average volume of 43,591. Neuphoria Therapeutics has a twelve month low of $3.64 and a twelve month high of $21.40. The company has a market capitalization of $26.70 million, a P/E ratio of -0.46 and a beta of 0.72. The stock has a 50 day simple moving average of $4.86 and a 200-day simple moving average of $4.44.

Neuphoria Therapeutics (NASDAQ:NEUP) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.47. Equities analysts predict that Neuphoria Therapeutics will post -4.07 EPS for the current year.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.